Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 2
2007 3
2008 3
2009 6
2010 3
2011 6
2012 7
2013 6
2014 5
2015 5
2016 5
2017 10
2018 5
2019 5
2020 8
2021 6
2022 8
2023 7
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Mei MG, et al. Among authors: palmer jm. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. Blood. 2022. PMID: 35316328 Free PMC article. Clinical Trial.
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, Aguilar B, Starr R, Weng L, Synold TW, Tran V, Wang S, Reik A, D'Apuzzo M, Ressler JA, Zhou Y, Mendel M, Gregory PD, Holmes MC, Tang WW, Forman SJ, Jensen MC, Badie B. Brown CE, et al. Among authors: palmer j. Neuro Oncol. 2022 Aug 1;24(8):1318-1330. doi: 10.1093/neuonc/noac024. Neuro Oncol. 2022. PMID: 35100373 Free PMC article. Clinical Trial.
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.
Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, Stein A, Pullarkat V, Salhotra A, Al Malki MM, Aribi A, Sandhu K, Thomas SH, Budde LE, Marcucci G, Brown CE, Forman SJ. Aldoss I, et al. Among authors: palmer j. Clin Cancer Res. 2023 Feb 16;29(4):742-753. doi: 10.1158/1078-0432.CCR-22-2038. Clin Cancer Res. 2023. PMID: 36255386 Free PMC article.
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY, Pak S, Mei M, Wang Y, Popplewell L, Baird JH, Herrera AF, Shouse G, Nikolaenko L, Zain J, Godfrey J, Htut M, Aribi A, Spielberger R, Mansour J, Forman SJ, Palmer J, Budde LE. Ong SY, et al. Among authors: palmer j. Am J Hematol. 2023 Nov;98(11):1751-1761. doi: 10.1002/ajh.27069. Epub 2023 Sep 5. Am J Hematol. 2023. PMID: 37668287 Free PMC article.
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo D, Tinajero J, Li S, Palmer J, Pourhassan H, Aribi A, Nakamura R, Stein A, Marcucci G, Salhotra A, Sandhu K, Pullarkat V, Ball B, Koller P. Ngo D, et al. Among authors: palmer j. Leuk Lymphoma. 2024 Mar;65(3):372-377. doi: 10.1080/10428194.2023.2292473. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164785
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M, Tsai NC, Palmer J, Armenian S, Chen R, Rosen S, Forman S, Popplewell L, Kwak L, Martin P, Maddocks K, Bond D, Herrera AF. Mei M, et al. Among authors: palmer j. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):537-542. doi: 10.1016/j.clml.2024.03.013. Epub 2024 Apr 10. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38693037 Clinical Trial.
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
Aldoss I, Shan H, Yang D, Clark MC, Al Malki M, Aribi A, Agrawal V, Sandhu K, Salhotra A, Pourhassan H, Koller P, Ali H, Artz A, Karras N, Pawlowska AB, Murphy L, Palmer J, Stein A, Marcucci G, Pullarkat V, Nakamura R, Forman SJ. Aldoss I, et al. Among authors: palmer j. Transplant Cell Ther. 2024 Aug;30(8):788.e1-788.e9. doi: 10.1016/j.jtct.2024.06.013. Epub 2024 Jun 12. Transplant Cell Ther. 2024. PMID: 38876428
Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review.
Wong JYC, Liu A, Han C, Dandapani S, Schultheiss T, Palmer J, Yang D, Somlo G, Salhotra A, Hui S, Al Malki MM, Rosenthal J, Stein A. Wong JYC, et al. Among authors: palmer j. Front Oncol. 2022 Oct 3;12:1003908. doi: 10.3389/fonc.2022.1003908. eCollection 2022. Front Oncol. 2022. PMID: 36263219 Free PMC article. Review.
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
Mei M, Palmer J, Tsai NN, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai JL, Htut M, Nakamura R, Al Malki MM, Herrera A, Wong J, Nademanee A. Mei M, et al. Among authors: palmer j. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e268-e276. doi: 10.1016/j.clml.2023.05.011. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37301631 Free PMC article. Clinical Trial.
89 results